Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19

Detalhes bibliográficos
Autor(a) principal: Silva Segundo, Raylton Jansen e
Data de Publicação: 2022
Outros Autores: Rufino, Júlia Passos, Sousa, Lunalva Gabrielli Veras, Rodrigues, Anna Eduarda Linhares, Falcão, Anna Lira Soares, Lima, Isabelle Carvalho de Melo, Cavalcanti , Lívia Ayres de Miranda, Dias, Ana Carolina Soares, Oliveira Filho, José Williams Gomes de
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Research, Society and Development
DOI: 10.33448/rsd-v11i6.29198
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/29198
Resumo: Introduction: azithromycin was one of the most employed medications during the beginning of the SARS-CoV2 pandemic, despite the lack of scientific basis for its use treatment of COVID-19. Its uncontrolled adoption has risen as a public health problem, as it promotes the appearance of drug-resistant bacterial strains, making it difficult to effectively treat many bacterial infections. Objective: to understand the implications of bacterial resistance to azithromycin in the treatment of infections in the fight against COVID-19. Methods: we surveyed a total of 38 scientific articles. The inclusion criteria were: studies whose central theme was bacterial resistance to azithromycin in the treatment of bacterioses and azithromycin in the fight against COVID-19, published from 2015 to 2022. Results: the widespread use of antibiotics may act in the selection of bacterial strains which had long held genetic traits for drug resistance, but which, not representing adaptative advantages, did not proliferate in the subsequent lineages. This direct proportionality between the widespread use and bacterial resistance to azithromycin is yet more aggravated in COVID-19 times, when part of the medical community and layman population self-medicates with azithromycin, without a scientific basis that justifies choosing this drug. Conclusion: there is a direct relationship between the indiscriminate use of azithromycin and a potential bacterial resistance to this drug. The appearance of resistant bacteria represents a serious public health problem due to the broad use of azithromycin against several bacterial infections.
id UNIFEI_d050d501f5bface0223ab8db9ba6b20e
oai_identifier_str oai:ojs.pkp.sfu.ca:article/29198
network_acronym_str UNIFEI
network_name_str Research, Society and Development
spelling Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19Resistencia bacteriana a la azitromicina: causas, efectos y la lucha contra el COVID-19Resistência bacteriana à azitromicina: causas, efeitos e combate ao COVID-19AzithromycinAntibacterial Drug ResistanceCOVID-19Virology.AzitromicinaFarmacorresistencia BacterianaCOVID-19Virología.AzitromicinaFarmacorresistência BacterianaCOVID-19Virologia.Introduction: azithromycin was one of the most employed medications during the beginning of the SARS-CoV2 pandemic, despite the lack of scientific basis for its use treatment of COVID-19. Its uncontrolled adoption has risen as a public health problem, as it promotes the appearance of drug-resistant bacterial strains, making it difficult to effectively treat many bacterial infections. Objective: to understand the implications of bacterial resistance to azithromycin in the treatment of infections in the fight against COVID-19. Methods: we surveyed a total of 38 scientific articles. The inclusion criteria were: studies whose central theme was bacterial resistance to azithromycin in the treatment of bacterioses and azithromycin in the fight against COVID-19, published from 2015 to 2022. Results: the widespread use of antibiotics may act in the selection of bacterial strains which had long held genetic traits for drug resistance, but which, not representing adaptative advantages, did not proliferate in the subsequent lineages. This direct proportionality between the widespread use and bacterial resistance to azithromycin is yet more aggravated in COVID-19 times, when part of the medical community and layman population self-medicates with azithromycin, without a scientific basis that justifies choosing this drug. Conclusion: there is a direct relationship between the indiscriminate use of azithromycin and a potential bacterial resistance to this drug. The appearance of resistant bacteria represents a serious public health problem due to the broad use of azithromycin against several bacterial infections.Introducción: la azitromicina fue uno de los medicamentos más empleados durante el inicio de la pandemia por SARS-CoV2, a pesar de la falta de base científica para su uso en el tratamiento de la COVID-19. Su adopción descontrolada se ha convertido en un problema de salud pública, ya que favorece la aparición de cepas bacterianas resistentes a los medicamentos, lo que dificulta el tratamiento eficaz de muchas infecciones bacterianas. Objetivo: comprender las implicaciones de la resistencia bacteriana a la azitromicina en el tratamiento de infecciones en la lucha contra la COVID-19. Métodos: se encuestaron un total de 38 artículos científicos. Los criterios de inclusión fueron: estudios cuyo tema central fuera la resistencia bacteriana a la azitromicina en el tratamiento de bacteriosis y azitromicina en la lucha contra el COVID-19, publicados de 2015 a 2022. Resultados: el uso generalizado de antibióticos puede actuar en la selección de cepas bacterianas que había tenido durante mucho tiempo rasgos genéticos para la resistencia a los medicamentos, pero que, al no representar ventajas adaptativas, no proliferaron en los linajes posteriores. Esta proporcionalidad directa entre el uso generalizado y la resistencia bacteriana a la azitromicina se agrava aún más en tiempos de COVID-19, cuando parte de la comunidad médica y la población profana se automedica con azitromicina, sin una base científica que justifique la elección de este fármaco. Conclusión: existe una relación directa entre el uso indiscriminado de azitromicina y una potencial resistencia bacteriana a este fármaco. La aparición de bacterias resistentes representa un grave problema de salud pública debido al amplio uso de la azitromicina contra diversas infecciones bacterianas.Introdução: a azitromicina foi um dos medicamentos mais empregados durante o início da pandemia de SARS-CoV2, apesar da falta de embasamento científico para seu uso no tratamento da COVID-19. Sua adoção descontrolada tem se tornado um problema de saúde pública, pois promove o aparecimento de cepas bacterianas resistentes aos medicamentos, dificultando o tratamento eficaz de muitas infecções bacterianas. Objetivo: compreender as implicações da resistência bacteriana à azitromicina no tratamento de infecções no combate à COVID-19. Métodos: pesquisamos um total de 38 artigos científicos. Os critérios de inclusão foram: estudos cujo tema central fosse resistência bacteriana à azitromicina no tratamento de bacterioses e azitromicina no combate à COVID-19, publicados de 2015 a 2022. Resultados: o uso generalizado de antibióticos pode atuar na seleção de cepas bacterianas que detinham por muito tempo traços genéticos para resistência a drogas, mas que, não representando vantagens adaptativas, não proliferaram nas linhagens subsequentes. Essa proporcionalidade direta entre o uso generalizado e a resistência bacteriana à azitromicina é ainda mais agravada em tempos de COVID-19, quando parte da comunidade médica e população leiga se automedicam com azitromicina, sem base científica que justifique a escolha desse medicamento. Conclusão: existe uma relação direta entre o uso indiscriminado de azitromicina e uma potencial resistência bacteriana a esta droga. O aparecimento de bactérias resistentes representa um grave problema de saúde pública devido ao amplo uso da azitromicina contra diversas infecções bacterianas.Research, Society and Development2022-04-27info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2919810.33448/rsd-v11i6.29198Research, Society and Development; Vol. 11 No. 6; e27711629198Research, Society and Development; Vol. 11 Núm. 6; e27711629198Research, Society and Development; v. 11 n. 6; e277116291982525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/29198/25211Copyright (c) 2022 Raylton Jansen e Silva Segundo; Júlia Passos Rufino; Lunalva Gabrielli Veras Sousa; Anna Eduarda Linhares Rodrigues; Anna Lira Soares Falcão; Isabelle Carvalho de Melo Lima; Lívia Ayres de Miranda Cavalcanti ; Ana Carolina Soares Dias; José Williams Gomes de Oliveira Filhohttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSilva Segundo, Raylton Jansen eRufino, Júlia PassosSousa, Lunalva Gabrielli VerasRodrigues, Anna Eduarda LinharesFalcão, Anna Lira SoaresLima, Isabelle Carvalho de MeloCavalcanti , Lívia Ayres de Miranda Dias, Ana Carolina SoaresOliveira Filho, José Williams Gomes de2022-05-13T18:04:10Zoai:ojs.pkp.sfu.ca:article/29198Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:46:20.603777Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19
Resistencia bacteriana a la azitromicina: causas, efectos y la lucha contra el COVID-19
Resistência bacteriana à azitromicina: causas, efeitos e combate ao COVID-19
title Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19
spellingShingle Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19
Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19
Silva Segundo, Raylton Jansen e
Azithromycin
Antibacterial Drug Resistance
COVID-19
Virology.
Azitromicina
Farmacorresistencia Bacteriana
COVID-19
Virología.
Azitromicina
Farmacorresistência Bacteriana
COVID-19
Virologia.
Silva Segundo, Raylton Jansen e
Azithromycin
Antibacterial Drug Resistance
COVID-19
Virology.
Azitromicina
Farmacorresistencia Bacteriana
COVID-19
Virología.
Azitromicina
Farmacorresistência Bacteriana
COVID-19
Virologia.
title_short Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19
title_full Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19
title_fullStr Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19
Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19
title_full_unstemmed Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19
Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19
title_sort Bacterial resistance to azithromycin: causes, effects, and the fight against COVID-19
author Silva Segundo, Raylton Jansen e
author_facet Silva Segundo, Raylton Jansen e
Silva Segundo, Raylton Jansen e
Rufino, Júlia Passos
Sousa, Lunalva Gabrielli Veras
Rodrigues, Anna Eduarda Linhares
Falcão, Anna Lira Soares
Lima, Isabelle Carvalho de Melo
Cavalcanti , Lívia Ayres de Miranda
Dias, Ana Carolina Soares
Oliveira Filho, José Williams Gomes de
Rufino, Júlia Passos
Sousa, Lunalva Gabrielli Veras
Rodrigues, Anna Eduarda Linhares
Falcão, Anna Lira Soares
Lima, Isabelle Carvalho de Melo
Cavalcanti , Lívia Ayres de Miranda
Dias, Ana Carolina Soares
Oliveira Filho, José Williams Gomes de
author_role author
author2 Rufino, Júlia Passos
Sousa, Lunalva Gabrielli Veras
Rodrigues, Anna Eduarda Linhares
Falcão, Anna Lira Soares
Lima, Isabelle Carvalho de Melo
Cavalcanti , Lívia Ayres de Miranda
Dias, Ana Carolina Soares
Oliveira Filho, José Williams Gomes de
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Silva Segundo, Raylton Jansen e
Rufino, Júlia Passos
Sousa, Lunalva Gabrielli Veras
Rodrigues, Anna Eduarda Linhares
Falcão, Anna Lira Soares
Lima, Isabelle Carvalho de Melo
Cavalcanti , Lívia Ayres de Miranda
Dias, Ana Carolina Soares
Oliveira Filho, José Williams Gomes de
dc.subject.por.fl_str_mv Azithromycin
Antibacterial Drug Resistance
COVID-19
Virology.
Azitromicina
Farmacorresistencia Bacteriana
COVID-19
Virología.
Azitromicina
Farmacorresistência Bacteriana
COVID-19
Virologia.
topic Azithromycin
Antibacterial Drug Resistance
COVID-19
Virology.
Azitromicina
Farmacorresistencia Bacteriana
COVID-19
Virología.
Azitromicina
Farmacorresistência Bacteriana
COVID-19
Virologia.
description Introduction: azithromycin was one of the most employed medications during the beginning of the SARS-CoV2 pandemic, despite the lack of scientific basis for its use treatment of COVID-19. Its uncontrolled adoption has risen as a public health problem, as it promotes the appearance of drug-resistant bacterial strains, making it difficult to effectively treat many bacterial infections. Objective: to understand the implications of bacterial resistance to azithromycin in the treatment of infections in the fight against COVID-19. Methods: we surveyed a total of 38 scientific articles. The inclusion criteria were: studies whose central theme was bacterial resistance to azithromycin in the treatment of bacterioses and azithromycin in the fight against COVID-19, published from 2015 to 2022. Results: the widespread use of antibiotics may act in the selection of bacterial strains which had long held genetic traits for drug resistance, but which, not representing adaptative advantages, did not proliferate in the subsequent lineages. This direct proportionality between the widespread use and bacterial resistance to azithromycin is yet more aggravated in COVID-19 times, when part of the medical community and layman population self-medicates with azithromycin, without a scientific basis that justifies choosing this drug. Conclusion: there is a direct relationship between the indiscriminate use of azithromycin and a potential bacterial resistance to this drug. The appearance of resistant bacteria represents a serious public health problem due to the broad use of azithromycin against several bacterial infections.
publishDate 2022
dc.date.none.fl_str_mv 2022-04-27
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/29198
10.33448/rsd-v11i6.29198
url https://rsdjournal.org/index.php/rsd/article/view/29198
identifier_str_mv 10.33448/rsd-v11i6.29198
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/29198/25211
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 11 No. 6; e27711629198
Research, Society and Development; Vol. 11 Núm. 6; e27711629198
Research, Society and Development; v. 11 n. 6; e27711629198
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1822178641249828864
dc.identifier.doi.none.fl_str_mv 10.33448/rsd-v11i6.29198